Inscription Capital LLC Purchases 6,718 Shares of ICU Medical, Inc. $ICUI

Inscription Capital LLC lifted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 407.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,365 shares of the medical instruments supplier’s stock after purchasing an additional 6,718 shares during the quarter. Inscription Capital LLC’s holdings in ICU Medical were worth $1,003,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ICUI. Simon Quick Advisors LLC purchased a new position in ICU Medical in the second quarter worth $275,000. AlphaQuest LLC boosted its stake in ICU Medical by 3,058.3% in the second quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock worth $200,000 after buying an additional 1,468 shares in the last quarter. Aaron Wealth Advisors LLC bought a new position in ICU Medical during the third quarter valued at approximately $521,000. Magnetar Financial LLC purchased a new position in shares of ICU Medical during the second quarter worth approximately $378,000. Finally, Hussman Strategic Advisors Inc. lifted its holdings in shares of ICU Medical by 40.0% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 29,400 shares of the medical instruments supplier’s stock worth $3,885,000 after acquiring an additional 8,400 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

ICUI stock opened at $153.23 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $175.51. The firm has a 50-day moving average of $145.91 and a 200 day moving average of $132.39. The company has a market cap of $3.78 billion, a P/E ratio of -494.27 and a beta of 0.80.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.60. The business had revenue of $533.30 million for the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The business’s revenue was down 8.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.59 EPS. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, sell-side analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on ICUI. Piper Sandler increased their target price on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. KeyCorp raised their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, ICU Medical presently has an average rating of “Moderate Buy” and an average price target of $175.67.

Insiders Place Their Bets

In related news, Director Elisha W. Finney sold 1,285 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the transaction, the director directly owned 3,995 shares in the company, valued at $560,977.90. This trade represents a 24.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Virginia Ruth Sanzone sold 930 shares of ICU Medical stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total transaction of $132,376.20. Following the transaction, the vice president directly owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. This trade represents a 14.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is currently owned by corporate insiders.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.